Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 30 holding rows worth $413,781,000.

Accession
0001172661-22-001465
Filed
2022-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2022

A holdings report, 30 entries on the cover page, a total value of $413,781,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $413,781,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
EXELIXIS INC COM30161Q104Stock1,300,000$29,471,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock920,000$28,124,000thousands by filing date
TRAVERE THERAPEUTICS INC89422G107COM1,010,000$26,028,000thousands by filing date
BICYCLE THERAPEUTICS PLC-ADR088786108SPONSORED ADS550,592$24,160,000thousands by filing date
JAZZ PHARMACEUTICALS PLC SHS USDG50871105Stock155,000$24,129,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW650,000$23,927,000thousands by filing date
CHINOOK THERAPEUTICS INC16961L106COM1,423,682$23,291,000thousands by filing date
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR360,000$22,327,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM85,000$22,182,000thousands by filing date
VAXCYTE INC COM92243G108Stock885,153$21,376,000thousands by filing date
RELMADA THERAPEUTICS INC75955J402COMMON STOCK790,000$21,322,000thousands by filing date
ANAPTYSBIO INC032724106COM700,000$17,318,000thousands by filing date
POINT BIOPHARMA GLOBAL INC730541109COM2,060,000$16,418,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock942,445$16,248,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM874,197$12,886,000thousands by filing date
RIGEL PHARMACEUTICALS INC766559603COMMON STOCK4,000,000$11,960,000thousands by filing date
KINIKSA PHARMACEUTICALS LTDG5269C101COM CL A1,118,067$11,114,000thousands by filing date
TRICIDA INC89610F101COM1,250,000$10,275,000thousands by filing date
AVIDITY BIOSCIENCES INC COM05370A108Stock500,000$9,235,000thousands by filing date
SILENCE THERAPEUTICS PLC82686Q101ADS444,443$8,444,000thousands by filing date
UROGEN PHARMA LTDM96088105COMMON STOCK873,424$7,608,000thousands by filing date
PIERIS PHARMACEUTICALS INC720795103COM2,199,076$6,663,000thousands by filing date
ARDELYX INC039697107COM4,761,905$5,095,000thousands by filing date
Ventyx Biosciences Inc92332V107Common Stock336,334$4,564,000thousands by filing date
ACUMEN PHARMACEUTICALS INC00509G209CMN928,282$3,630,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock1,170,000$3,393,000thousands by filing date
CINCOR PHARMA INC17240Y109COM79,670$1,397,000thousands by filing date
NEKTAR THERAPEUTICS640268108COM100,000$539,000thousands by filing datecall
PASSAGE BIO INC702712100COM113,900$353,000thousands by filing date
Rafael Holdings Inc Class B75062E106COM121,000$304,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-22-001465this filing2022-05-16acceptance time not in the bulk data set